Sickle cell pain crisis: watch the chest
Every day of a pain admission
The chest film got worse
Definitions differ. The guidelines ask for the infiltrate plus one sign. The National Acute Chest Syndrome Study Group used a new infiltrate plus at least one of chest pain, fever above 38.5 C, fast breathing, wheeze or cough, or low oxygen.
Two things arrive around day 3
They can look alike on the film. Before the label, weigh the patient, add up the balance, look at the legs. On the Dutch protocol of 3 liters a day, 21 of 100 patients became overloaded (18% of adults). A top-up transfusion during the admission raised the odds six-fold.
The numbers
- 671 episodes: 13% needed a ventilator, 3% died. Adults do worse than children.
- Per 100 patient-years: SS 12.8, S-beta-zero 9.4, SC 5.2, S-beta-plus 3.9. Prevention and antibiotics are the same for every genotype. Transfusion is not: in SC and S-beta-plus the baseline hemoglobin is higher, so call hematology before any top-up.
- Steroids: not routinely. They shorten the episode and bring the patient back with pain.
- Hydroxyurea takes months to work, so it does not treat this episode. It prevents the next one: chest syndrome in 25 vs 51 patients.
- New, not yet in guidelines: in a 2025 randomized trial of 172 adults with no clot on CT angiogram, therapeutic-dose tinzaparin for 7 days resolved the episode faster than prophylactic-dose tinzaparin (hazard ratio 0.71, confidence interval just under 1.0; about 4.8 vs 6.1 days), with no major bleeding in either arm and less opioid use.
Sources
Retrieved from PubMed, read on Oct 15, 2026. The NHLBI 2014 report, the British 2015 guideline, the ASH 2020 transfusion guideline, the 2025 anticoagulation trial and the fluid overload study were read in full text. The 1995 and 2000 trials were read as abstracts.
- Vichinsky EP, et al. Causes and outcomes of the acute chest syndrome. N Engl J Med 2000. doi:10.1056/NEJM200006223422502
- Bellet PS, et al. Incentive spirometry to prevent acute pulmonary complications. N Engl J Med 1995. doi:10.1056/NEJM199509143331104
- NHLBI. Evidence-based management of sickle cell disease, expert panel report 2014. Report. Summary: Yawn BP, et al. JAMA 2014. doi:10.1001/jama.2014.10517
- Howard J, et al. British guideline on acute chest syndrome in sickle cell disease. Br J Haematol 2015. doi:10.1111/bjh.13348
- Chou ST, et al. ASH 2020 guidelines for sickle cell disease: transfusion support. Blood Adv 2020. doi:10.1182/bloodadvances.2019001143
- Gaartman AE, et al. Fluid overload due to intravenous fluid therapy for vaso-occlusive crisis. Br J Haematol 2021. doi:10.1111/bjh.17696
- Castro O, et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. Blood 1994;84:643. PMID 7517723
- Strouse JJ, et al. Corticosteroids and readmission after acute chest syndrome. Pediatr Blood Cancer 2008. doi:10.1002/pbc.21336
- Mekontso Dessap A, et al. TASC: prophylactic vs therapeutic anticoagulation in acute chest syndrome. Am J Respir Crit Care Med 2025. doi:10.1164/rccm.202409-1727OC
- Creary SE, Strouse JJ. Hydroxyurea and transfusion therapy for sickle cell disease, ASH pocket guide adapted from the NHLBI 2014 report. Guide
- Charache S, et al. Hydroxyurea in sickle cell anemia. N Engl J Med 1995. doi:10.1056/NEJM199505183322001
Growth factor after chemotherapy
Who gets it
When
Label and the pooled data: not the same day. Label: pegfilgrastim not within 14 days of the next dose. Every-2-week dose-dense regimens use it on day 2 anyway, on guideline support. Weekly regimens get daily filgrastim.
Doses
| Drug | Dose | Fits |
|---|---|---|
| Filgrastim, short acting | 5 mcg/kg a day (300 or 480 mcg) until counts recover | Any cycle length |
| Pegfilgrastim, long acting: Neulasta lasts | 6 mg once per cycle | Cycles of 2 weeks or longer |
Bone pain in 1 patient in 3. Naproxen 500 mg twice a day for 5 to 8 days trims it modestly (71% to 61%); loratadine 10 mg daily did about as well with fewer side effects, which matters when platelets or kidneys are the issue.
Sources
Retrieved from PubMed and from FDA labels on DailyMed, read on Oct 15, 2026. The guideline was read in full text.
- Gyawali B, et al. WBC growth factors: ASCO guideline update. J Clin Oncol 2026;44:812-824. doi:10.1200/JCO-25-02938
- Crawford J, et al. Filgrastim in small-cell lung cancer. N Engl J Med 1991. doi:10.1056/NEJM199107183250305
- Vogel CL, et al. First-cycle pegfilgrastim with docetaxel. J Clin Oncol 2005. doi:10.1200/JCO.2005.09.102
- Ma X, et al. Same-day versus next-day pegfilgrastim, meta-analysis. BMJ Support Palliat Care, 2021 online. doi:10.1136/bmjspcare-2020-002532
- Kirshner JJ, et al. Naproxen for pegfilgrastim bone pain. J Clin Oncol 2012. doi:10.1200/JCO.2011.37.8364
- Kirshner JJ, et al. NOLAN: naproxen or loratadine. Support Care Cancer 2018. doi:10.1007/s00520-017-3959-2
- Pegfilgrastim (Neulasta) prescribing information, DailyMed. Label
- Filgrastim (Neupogen) prescribing information, DailyMed. Label
Platelets over a million
What to do with the number
8 of 10 counts above 1 million on the ward are reactive. In the clinic, more than half are a myeloid neoplasm. After surgery the count is usually gone by one month (84% in the Mayo series). Reactive counts rarely clot: in the Griesshammer series the events were venous, and only in patients with another risk factor.
Why a million matters in essential thrombocythemia
Platelets do not make blood thick
"Platelets 1,200, concern for hyperviscosity" is a common line in an admission note. It mixes two different problems. Added Oct 18, 2026.
Blurred vision, nosebleeds, confusion, retinal vein engorgement.
Treatment: plasma exchange, started on the clinical picture, not on a viscosity number.
Treatment: phlebotomy, or cytoreduction.
Headache with iron deficiency: think cerebral venous thrombosis, not viscosity.In 152 patients with cerebral venous thrombosis against 2,916 controls, anemia was present in 27% versus 6.5%, adjusted odds ratio 4.4 (Coutinho 2015). The anemia is the risk factor, independent of the platelets. The test is a venogram of the brain (magnetic resonance or CT venography); the treatment, if positive, is anticoagulation, and the platelet count does not forbid it.
Essential thrombocythemia by risk group
| Group | Who | Treatment |
|---|---|---|
| Very low | 60 or younger, no clot, JAK2 negative | Observe, or aspirin with cardiovascular risk factors |
| Low | 60 or younger, no clot, JAK2 positive | Aspirin, twice daily is reasonable |
| Intermediate | Over 60, no clot, JAK2 negative | Aspirin (Mayo algorithm; ELN still gives hydroxyurea over 60) |
| High | Prior clot, or over 60 with JAK2 | Hydroxyurea + aspirin |
Sources
Retrieved from PubMed, read on Oct 15, 2026.
- Griesshammer M, et al. Aetiology of thrombocytosis in 732 patients. J Intern Med 1999. doi:10.1046/j.1365-2796.1999.00452.x
- Buss DH, et al. Extreme thrombocytosis in 280 patients. Am J Med 1994. doi:10.1016/0002-9343(94)90150-3
- Hsieh RW, et al. Extreme thrombocytosis in adults, Mayo Clinic. Mayo Clin Proc 2019. doi:10.1016/j.mayocp.2019.01.041
- Bleeker JS, Hogan WJ. Thrombocytosis: evaluation and risk-based management. Thrombosis 2011. doi:10.1155/2011/536062
- Budde U, et al. Acquired von Willebrand's disease in the myeloproliferative syndrome. Blood 1984;64:981. PMID 6333259
- van Genderen PJ, et al. Acquired von Willebrand factor deficiency in essential thrombocythaemia and reactive thrombocytosis. Br J Haematol 1996. doi:10.1046/j.1365-2141.1996.d01-1729.x
- Rottenstreich A, et al. Acquired von Willebrand syndrome in essential thrombocythemia. Eur J Intern Med 2017. doi:10.1016/j.ejim.2016.11.011
- Gurumurthy G, et al. Bleeding complications in JAK2-variant essential thrombocythemia: a revisit in 2025. EJHaem 2025. doi:10.1002/jha2.70088
- Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia treatment algorithm 2018. Blood Cancer J 2018. doi:10.1038/s41408-017-0041-8
- Barbui T, et al. Revised IPSET-thrombosis. Blood Cancer J 2015. doi:10.1038/bcj.2015.94
- Barbui T, et al. European LeukemiaNet recommendations. Leukemia 2018. doi:10.1038/s41375-018-0077-1
- Gangat N, et al. One thousand patients with essential thrombocythemia. Blood Cancer J 2024. doi:10.1038/s41408-023-00972-x
- Cortelazzo S, et al. Hydroxyurea in high-risk essential thrombocythemia. N Engl J Med 1995. doi:10.1056/NEJM199504273321704
- Gertz MA. Acute hyperviscosity: syndromes and management. Blood 2018. doi:10.1182/blood-2018-06-846816 (added Oct 18, 2026)
- Stone MJ, Bogen SA. Evidence-based focused review of management of hyperviscosity syndrome. Blood 2012. doi:10.1182/blood-2011-04-347690 (added Oct 18, 2026)
- Coutinho JM, et al. Association between anemia and cerebral venous thrombosis: case-control study. Stroke 2015. doi:10.1161/STROKEAHA.115.009843 (added Oct 18, 2026)
Iron in the sick inpatient
Three steps
Ferritin: how high can it be and still be iron deficiency?
Ferritin in ng/mL, not to scale. Dark: ferritin decides (in kidney disease, with the saturation shown). Pale: only with the low saturation shown. Stop iron at a ferritin of 700 or a saturation of 40% or more. Inflamed inpatient: ferritin under 100 with saturation under 20% (Weiss 2019). Kidney thresholds are from the January 2026 guideline.
IV iron products
| Product | Label dose | Know this |
|---|---|---|
| Iron sucrose | 200 mg x 5 | |
| Ferric gluconate | 125 mg x 8 | At dialysis sessions |
| Ferric carboxymaltose | 750 mg x 2, or 1,000 mg once | Low phosphate, boxed warning |
| Ferric derisomaltose | 1,000 mg once | At 50 kg or more |
| Ferumoxytol | 510 mg x 2 | Boxed anaphylaxis warning |
| Iron dextran | 100 mg a day | Boxed anaphylaxis warning, test dose, highest reaction rate of the group (Wang 2015) |
Hold IV iron during bacteremia. Erythropoietin comes after iron, never with uncontrolled blood pressure. Kidney disease: keep hemoglobin under 11 to 11.5. Chemotherapy anemia: start under 10 and only if the intent is not cure.
Sources
Retrieved from PubMed and from FDA labels on DailyMed, read on Oct 15, 2026. The 2026 kidney guideline was read through its European commentary, not the primary text.
- Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. Blood 2019. doi:10.1182/blood-2018-06-856500
- Ko CW, et al. AGA guideline on gastrointestinal evaluation of iron deficiency anemia. Gastroenterology 2020. doi:10.1053/j.gastro.2020.06.046
- Snook J, et al. British Society of Gastroenterology guideline, iron deficiency anaemia in adults. Gut 2021. doi:10.1136/gutjnl-2021-325210
- KDIGO 2026 guideline, anemia in chronic kidney disease. Kidney Int 2026;109(1S):S1-S99. doi:10.1016/j.kint.2025.06.006
- Del Vecchio L, et al. European commentary on KDIGO 2026. Nephrol Dial Transplant 2026. doi:10.1093/ndt/gfag014
- Masini G, et al. Criteria for iron deficiency in heart failure. J Am Coll Cardiol 2022. doi:10.1016/j.jacc.2021.11.039
- Wolf M, et al. Hypophosphatemia after ferric carboxymaltose. JAMA 2020. doi:10.1001/jama.2019.22450
- Wang C, et al. Anaphylaxis risk with IV iron products. JAMA 2015. doi:10.1001/jama.2015.15572
- Pfeffer MA, et al. TREAT: darbepoetin in diabetes and kidney disease. N Engl J Med 2009. doi:10.1056/NEJMoa0907845
- Longcroft-Wheaton G. Fecal immunochemical testing in iron deficiency anemia. J Clin Gastroenterol 2026. doi:10.1097/MCG.0000000000002338
- Pham J, et al. Fecal immunochemical test accuracy in iron deficiency anemia, meta-analysis. Crit Rev Oncol Hematol 2024. doi:10.1016/j.critrevonc.2024.104439
- Pearce RF, et al. Inpatient stool occult blood testing. South Med J 2026. doi:10.14423/SMJ.0000000000001973
- Epoetin alfa, ferric carboxymaltose, iron dextran, ferumoxytol, iron sucrose, ferric derisomaltose and ferric gluconate prescribing information, DailyMed. Labels